Matisse Capital grew its position in PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 112.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 22,285 shares of the company's stock after acquiring an additional 11,817 shares during the quarter. Matisse Capital's holdings in PROCEPT BioRobotics were worth $1,794,000 at the end of the most recent reporting period.
Other hedge funds have also modified their holdings of the company. Values First Advisors Inc. purchased a new stake in PROCEPT BioRobotics in the 3rd quarter valued at $27,000. Raleigh Capital Management Inc. acquired a new position in PROCEPT BioRobotics in the fourth quarter valued at $32,000. Wilmington Savings Fund Society FSB purchased a new stake in shares of PROCEPT BioRobotics in the third quarter valued at about $64,000. Canton Hathaway LLC acquired a new stake in shares of PROCEPT BioRobotics during the third quarter worth about $66,000. Finally, Nisa Investment Advisors LLC grew its holdings in shares of PROCEPT BioRobotics by 178.3% during the third quarter. Nisa Investment Advisors LLC now owns 1,113 shares of the company's stock worth $89,000 after buying an additional 713 shares during the last quarter. 89.46% of the stock is currently owned by hedge funds and other institutional investors.
PROCEPT BioRobotics Price Performance
PRCT stock traded down $1.23 on Friday, reaching $69.56. 557,671 shares of the company's stock were exchanged, compared to its average volume of 870,427. The stock has a fifty day moving average of $82.36 and a 200-day moving average of $79.43. The firm has a market cap of $3.63 billion, a PE ratio of -35.67 and a beta of 1.03. The company has a quick ratio of 5.07, a current ratio of 6.02 and a debt-to-equity ratio of 0.21. PROCEPT BioRobotics Co. has a twelve month low of $45.20 and a twelve month high of $103.81.
Analysts Set New Price Targets
PRCT has been the subject of several analyst reports. Truist Financial reaffirmed a "buy" rating and set a $105.00 price objective (up from $95.00) on shares of PROCEPT BioRobotics in a research note on Wednesday, October 30th. Morgan Stanley assumed coverage on PROCEPT BioRobotics in a research note on Monday, December 2nd. They set an "overweight" rating and a $105.00 price target for the company. Wells Fargo & Company reaffirmed an "overweight" rating and set a $112.00 price target on shares of PROCEPT BioRobotics in a report on Tuesday, December 3rd. Finally, Jefferies Financial Group initiated coverage on shares of PROCEPT BioRobotics in a research note on Thursday, November 14th. They issued a "hold" rating and a $95.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, PROCEPT BioRobotics has a consensus rating of "Moderate Buy" and an average price target of $97.86.
Get Our Latest Report on PROCEPT BioRobotics
Insider Transactions at PROCEPT BioRobotics
In other PROCEPT BioRobotics news, EVP Alaleh Nouri sold 28,092 shares of the company's stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $97.13, for a total value of $2,728,575.96. Following the sale, the executive vice president now owns 52,472 shares of the company's stock, valued at approximately $5,096,605.36. This represents a 34.87 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Reza Zadno sold 26,423 shares of PROCEPT BioRobotics stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $97.22, for a total value of $2,568,844.06. Following the transaction, the chief executive officer now directly owns 152,762 shares of the company's stock, valued at $14,851,521.64. This trade represents a 14.75 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 107,355 shares of company stock valued at $10,327,788 in the last ninety days. 17.40% of the stock is currently owned by company insiders.
About PROCEPT BioRobotics
(
Free Report)
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).
Further Reading
Before you consider PROCEPT BioRobotics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PROCEPT BioRobotics wasn't on the list.
While PROCEPT BioRobotics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
